O’Shaughnessy, Joyce

Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 3,270

Ribociclib as first-line therapy for HR-positive, advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 2,039

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

Cited by 1,711

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 1,274

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., et al. (2018) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 876

Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer

Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 874

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 807

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., et al. (2022) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 791

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.

Goetz, M. P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I. H., Campone, M., Chen, S.-C., Manso, L. M., Paluch-Shimon, S., et al. (2024) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 238

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

Di Leo, A., O’Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., Hardebeck, M. C., Smith, I. C., Llombart-Cussac, A., Goetz, M. P., et al. (2018) · npj Breast Cancer

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 66

Development and validation of a human-supervised AI-augmented living oncology evidence platform: a breast cancer pilot study

Rugo, H., Forsythe, A., Flora, D., Glück, S., Grieve, S., Campden, R., Liu, R. J., Musat, M., Rege, J. M., Kaufman, P. A., et al. (2026) · ESMO Real World Data and Digital Oncology

Artificial Intelligence in Healthcare and EducationMeta-analysis and systematic reviews

Cited by 0